ATE543498T1 - Benzotriazol kinasemodulatoren - Google Patents
Benzotriazol kinasemodulatorenInfo
- Publication number
- ATE543498T1 ATE543498T1 AT07803049T AT07803049T ATE543498T1 AT E543498 T1 ATE543498 T1 AT E543498T1 AT 07803049 T AT07803049 T AT 07803049T AT 07803049 T AT07803049 T AT 07803049T AT E543498 T1 ATE543498 T1 AT E543498T1
- Authority
- AT
- Austria
- Prior art keywords
- benzotriazole
- kinase modulators
- modulators
- kinase
- benzotriazole kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 239000012964 benzotriazole Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84309006P | 2006-09-08 | 2006-09-08 | |
| PCT/EP2007/059040 WO2008028860A1 (en) | 2006-09-08 | 2007-08-30 | Benzotriazole kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE543498T1 true ATE543498T1 (de) | 2012-02-15 |
Family
ID=38893293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07803049T ATE543498T1 (de) | 2006-09-08 | 2007-08-30 | Benzotriazol kinasemodulatoren |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8962622B2 (de) |
| EP (1) | EP2066319B1 (de) |
| JP (1) | JP5325783B2 (de) |
| KR (1) | KR101177729B1 (de) |
| CN (1) | CN101511359B (de) |
| AR (1) | AR062666A1 (de) |
| AT (1) | ATE543498T1 (de) |
| AU (1) | AU2007293917B2 (de) |
| BR (1) | BRPI0717035B8 (de) |
| CA (1) | CA2662998C (de) |
| CL (1) | CL2007002572A1 (de) |
| ES (1) | ES2378577T3 (de) |
| IL (1) | IL197015A (de) |
| MX (1) | MX2009002229A (de) |
| PE (1) | PE20080659A1 (de) |
| TW (1) | TW200819440A (de) |
| WO (1) | WO2008028860A1 (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| CN101547917A (zh) | 2006-12-08 | 2009-09-30 | 霍夫曼-拉罗奇有限公司 | 用作jnk调节剂的取代的嘧啶类化合物及它们的应用 |
| WO2009053269A1 (en) * | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
| EP2283009B1 (de) * | 2008-05-16 | 2012-08-29 | F. Hoffmann-La Roche AG | Jnk-hemmer |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| CN102325771B (zh) | 2009-02-24 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 作为jnk调节剂的咪唑并[1,2-a]吡啶类 |
| SG178321A1 (en) * | 2009-08-10 | 2012-03-29 | Hoffmann La Roche | Inhibitors of jnk |
| BR112012030814A2 (pt) * | 2010-06-04 | 2019-09-24 | Hoffmann La Roche | inibidores de jnk |
| JP5916719B2 (ja) * | 2010-06-04 | 2016-05-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊｎｋの阻害剤として有用な２−アミノ−ピリミジン誘導体 |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| AU2010362444B2 (en) | 2010-10-14 | 2015-08-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| EP2673347B1 (de) * | 2011-02-09 | 2018-09-12 | The Lubrizol Corporation | Schmiermittelzusammensetzungen enthaltend ein asphaltendispergens |
| EP2567959B1 (de) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| HRP20181908T1 (hr) * | 2013-02-25 | 2019-01-11 | Aurigene Discovery Technologies Limited | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| ES2870085T3 (es) | 2013-06-26 | 2021-10-26 | Xigen Inflammation Ltd | Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis |
| CN106458990B (zh) | 2014-04-04 | 2019-06-07 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| CN106661050A (zh) * | 2014-06-16 | 2017-05-10 | 阿林齐生物制药公司 | 用于治疗和预防神经系统的退行性疾病的p38和JNK MAPK抑制剂 |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
| CN108117523B (zh) * | 2016-11-29 | 2021-05-07 | 上海医药工业研究院 | 卤代尿嘧啶类化合物的制备方法 |
| MA48459B1 (fr) | 2017-04-24 | 2021-09-30 | Aurigene Discovery Tech Ltd | Méthodes d'utilisation de dérivés de benzotriazole trisubstitués en tant qu'inhibiteurs de dihydroorotate oxygénase |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| KR102861339B1 (ko) | 2018-02-20 | 2025-09-19 | 르 라보레또레 쎄르비에르 | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| EP4215244A4 (de) * | 2020-09-15 | 2025-02-26 | Mitsubishi Tanabe Pharma Corporation | Triazinverbindungssalz, kristallform davon und herstellungsverfahren dafür |
| CN114456126A (zh) * | 2022-02-26 | 2022-05-10 | 郑州萃智医药科技有限公司 | 一种化合物的合成方法 |
| CN115677595B (zh) * | 2022-10-26 | 2024-06-14 | 江苏睿实生物科技有限公司 | 一种2,4,5-三氯嘧啶的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| JP2003503351A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害化合物 |
| EP1257546A1 (de) | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitoren |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| JP4688876B2 (ja) | 2004-06-10 | 2011-05-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| ES2336625T3 (es) | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
-
2007
- 2007-08-30 EP EP07803049A patent/EP2066319B1/de active Active
- 2007-08-30 WO PCT/EP2007/059040 patent/WO2008028860A1/en not_active Ceased
- 2007-08-30 MX MX2009002229A patent/MX2009002229A/es active IP Right Grant
- 2007-08-30 JP JP2009527118A patent/JP5325783B2/ja active Active
- 2007-08-30 AT AT07803049T patent/ATE543498T1/de active
- 2007-08-30 CN CN2007800334496A patent/CN101511359B/zh active Active
- 2007-08-30 BR BRPI0717035A patent/BRPI0717035B8/pt active IP Right Grant
- 2007-08-30 ES ES07803049T patent/ES2378577T3/es active Active
- 2007-08-30 AU AU2007293917A patent/AU2007293917B2/en active Active
- 2007-08-30 CA CA2662998A patent/CA2662998C/en active Active
- 2007-08-30 KR KR1020097004741A patent/KR101177729B1/ko active Active
- 2007-09-05 TW TW096133095A patent/TW200819440A/zh unknown
- 2007-09-05 CL CL200702572A patent/CL2007002572A1/es unknown
- 2007-09-06 AR ARP070103923A patent/AR062666A1/es active IP Right Grant
- 2007-09-06 PE PE2007001197A patent/PE20080659A1/es active IP Right Grant
- 2007-09-07 US US11/899,758 patent/US8962622B2/en active Active
-
2009
- 2009-02-12 IL IL197015A patent/IL197015A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PE20080659A1 (es) | 2008-05-17 |
| IL197015A (en) | 2013-12-31 |
| BRPI0717035B8 (pt) | 2021-05-25 |
| ES2378577T3 (es) | 2012-04-16 |
| KR20090040908A (ko) | 2009-04-27 |
| AR062666A1 (es) | 2008-11-26 |
| CA2662998A1 (en) | 2008-03-13 |
| MX2009002229A (es) | 2009-03-16 |
| BRPI0717035B1 (pt) | 2021-05-04 |
| AU2007293917B2 (en) | 2013-01-31 |
| US20080103142A1 (en) | 2008-05-01 |
| CN101511359A (zh) | 2009-08-19 |
| KR101177729B1 (ko) | 2012-09-07 |
| EP2066319B1 (de) | 2012-02-01 |
| EP2066319A1 (de) | 2009-06-10 |
| TW200819440A (en) | 2008-05-01 |
| IL197015A0 (en) | 2009-11-18 |
| AU2007293917A1 (en) | 2008-03-13 |
| WO2008028860A1 (en) | 2008-03-13 |
| CA2662998C (en) | 2015-10-06 |
| US8962622B2 (en) | 2015-02-24 |
| JP2010502668A (ja) | 2010-01-28 |
| CL2007002572A1 (es) | 2008-04-18 |
| JP5325783B2 (ja) | 2013-10-23 |
| CN101511359B (zh) | 2012-09-05 |
| BRPI0717035A2 (pt) | 2014-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE543498T1 (de) | Benzotriazol kinasemodulatoren | |
| FR21C1019I2 (fr) | Inhibiteurs de kinase de type biaryl-meta-pyrimidine | |
| BRPI0716781A2 (pt) | Inibidores da quinase | |
| BRPI0716549A2 (pt) | moduladores de quinase associada de interleucina-1 | |
| HRP20250383T3 (hr) | Tablete koje sadrže eltrombopag olamin | |
| EP2089308A4 (de) | Spender | |
| ATE488505T1 (de) | Kinasehemmer auf hydantoinbasis | |
| EP2162132A4 (de) | Heterozyklische kinasemodulatoren | |
| CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| DK2069312T3 (da) | Pyridazinonderivater | |
| EP2040546A4 (de) | Tyrosinkinasehemmer | |
| EP2094447A4 (de) | Mini-heftgerät | |
| AT504580A3 (de) | Scan-einrichtung | |
| DK2242743T3 (da) | Aminopyrazolderivater | |
| BRPI0817843A2 (pt) | Inibidores da quinase c-fms | |
| IL194814A0 (en) | Mglur5 modulators i | |
| BRPI0821773A2 (pt) | Monossebacato derivado de pirazol | |
| EP2197705A4 (de) | Rückspiegel | |
| ATE546437T1 (de) | Aminomethyl-4-imidazole | |
| EP2104405A4 (de) | Neutralisator | |
| EP2009411A4 (de) | Kombinations-ausgleichsvorrichtung | |
| EP2050612A4 (de) | Akkumulator | |
| DK2221298T3 (da) | Phenylpyrazolderivater | |
| DE112007003147A5 (de) | Rohr-Biegevorrichtung | |
| DE602007009224D1 (de) | R-cellular-systemen |